Targeted proteomic technologies, such as SRM, could replace the most widely used clinical tests for CRC, such as the fecal occult blood test or CEA, and would be powerful tools for early diagnosis of CRC. This evidence concerns the gene CEACAM5 and colorectal carcinoma.